KROS Keros Therapeutics, Inc.
Price Chart
Executive Summary
Keros Therapeutics presented additional Phase 1 data for rinvatercept (KER-065) at a clinical conference, showing target engagement, favorable changes in muscle and bone mass, and a good safety profile in healthy volunteers. The data support advancing rinvatercept into two Phase 2 trials for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS), representing a meaningful step in the clinical development of the drug.
Actionable Insight
Traders should monitor upcoming trial initiations and enrollment timelines for the Phase 2 studies in DMD and ALS, as these will be key catalysts. The positive biomarker and safety data reduce near-term clinical risk, potentially supporting valuation upside ahead of clinical milestones.
Key Facts
- Keros presented additional Phase 1 data for rinvatercept in healthy volunteers, confirming target engagement and mechanism of action.
- Rinvatercept was well-tolerated with no serious adverse events or dose-limiting toxicities.
- Treatment led to increased muscle mass, decreased fat mass, and improved bone mineral density.
- Proteomic data showed anti-fibrotic and anti-inflammatory effects, aligning with preclinical findings.
- Company plans to advance rinvatercept into Phase 2 trials for DMD and ALS.
Financial Impact
No direct financial impact reported; potential long-term value creation if Phase 2 trials succeed.
Risk Factors
- Phase 2 trials may not replicate Phase 1 results in patient populations.
- Clinical development timelines could be delayed due to enrollment, regulatory, or manufacturing challenges.
- Competition exists in both DMD and ALS spaces with other biotech firms developing novel therapies.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251751 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 14, 2026
6d ago
|
8-K
| $12.00 awaiting T+5 | awaiting T+5 | — | $10.98 (+8.50%) |
|
May 14, 2026
6d ago
|
Press Release
| $12.00 awaiting T+5 | awaiting T+5 | — | $10.98 (+8.50%) |
|
Apr 22, 2026
28d ago
|
DEFA14A
| $11.56 $11.10 | ▼ −3.98% | ▼ −5.46% | $10.98 (−5.02%) |
|
Apr 1, 2026
7w ago
|
144
| $11.69 $12.49 | ▲ +6.84% | ▲ +3.08% | $10.98 (−6.07%) |
|
Mar 9, 2026
10w ago
|
Press Release
| $11.35 $11.03 | ▼ −2.82% | ▼ −1.46% | $10.98 (−3.26%) |
|
Mar 4, 2026
11w ago
|
8-K
| $11.71 $10.99 | ▼ −6.15% | ▼ −3.91% | $10.98 (−6.23%) |
|
Mar 4, 2026
11w ago
|
8-K
| $11.71 $10.99 | ▼ −6.15% | ▼ −3.91% | $10.98 (−6.23%) |
|
Mar 4, 2026
11w ago
|
Press Release
| $11.71 $10.99 | ▼ −6.15% | ▼ −3.91% | $10.98 (−6.23%) |
|
Feb 28, 2026
11w ago
|
Institutional Cluster
| $13.91 $11.35 | ▼ −18.40% | ▼ −17.20% | $10.98 (−21.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access